Αρχική World News Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma After...

Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma After Radical Surgery

In the CheckMate 274 study, median disease-free survival (DFS) was significantly longer with adjuvant nivolumab than with placebo among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery with curative intent. The study data show a significant and clinically meaningful benefit of adjuvant nivolumab, both in the intention-to-treat (ITT) population and in patients with a PD-L1 expression level of 1% or more. Adjuvant nivolumab was associated with the expected side effects. The findings are published by Dr. Dean F. Bajorin of the Department of Medicine, Memorial Sloan Kettering Cancer Center in New York, NY, US and colleagues in 3rd June 2021 issue of The New England Journal of Medicine.  

The authors wrote in the study background that radical surgery involving cystectomy for tumours arising in the bladder or nephroureterectomy for tumours arising in the upper urinary tract is the standard of care for patients with muscle-invasive urothelial carcinoma. Although radical surgery is performed with curative intent, more than 50% of patients with pathological evidence of cancer invading through the muscularis propria or involving the regional lymph nodes will have metastatic recurrence. 

There is no consensus regarding routine adjuvant cisplatin-based chemotherapy and some patients with urothelial carcinoma are ineligible for or decline neoadjuvant cisplatin-based chemotherapy. Despite a high risk of metastatic recurrence, no standard adjuvant systemic therapies have been shown to improve outcomes in patients with pathological evidence of residual disease after neoadjuvant cisplatin-based chemotherapy.

The phase III, multicentre, double-blind, randomised CheckMate 274 study was performed to evaluate the efficacy and safety of adjuvant nivolumab, as compared with placebo, in patients with muscle-invasive urothelial carcinoma after radical surgery. Patients received in a 1:1 ratio either nivolumab or placebo every 2 weeks for up to 1 year. Neoadjuvant cisplatin-based chemotherapy before study entry was allowed. The primary endpoints were DFS in ITT population and among patients with a tumour PD-L1 expression level of 1% or more. Survival free from recurrence outside the urothelial tract was a secondary endpoint.

In total, 353 patients were assigned to receive nivolumab and 356 to receive placebo. The median DFS in the ITT population was 20.8 months (95% confidence interval [CI] 16.5 to 27.6) with nivolumab and 10.8 months (95% CI 8.3 to 13.9) with placebo. The percentage of patients who were alive and disease-free at 6 months was 74.9% with nivolumab and 60.3% with placebo (hazard ratio [HR] for disease recurrence or death, 0.70; 98.22% CI 0.55 to 0.90; p < 0.001). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 74.5% and 55.7%, respectively (HR 0.55; 98.72% CI 0.35 to 0.85; p < 0.001).

The median survival free from recurrence outside the urothelial tract in the ITT population was 22.9 months (95% CI 19.2 to 33.4) with nivolumab and 13.7 months (95% CI 8.4 to 20.3) with placebo. The percentage of patients who were alive and free from recurrence outside the urothelial tract at 6 months was 77.0% with nivolumab and 62.7% with placebo (HR for recurrence outside the urothelial tract or death, 0.72; 95% CI 0.59 to 0.89). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 75.3% and 56.7% (HR 0.55; 95% CI 0.39 to 0.79).

Treatment-related adverse events of grade 3 or higher occurred in 17.9% of the nivolumab group and in 7.2% of the placebo group. Two treatment-related deaths due to pneumonitis were noted in the nivolumab group.

The authors concluded that in this study involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, DFS was longer with adjuvant nivolumab than with placebo in the ITT population and among patients with a PD-L1 expression level of 1% or more. The study investigators plan further follow-up to assess overall survival.

The study was funded by Bristol Myers Squibb and Ono Pharmaceutical. The authors thanked the staff of Dako, an Agilent Technologies company, for collaborative development of the PD-L1 IHC 28-8 pharmDx assay. 

Reference

Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 2021;384:2102-2114. DOI: 10.1056/NEJMoa2034442.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

10 Ways You Can Nurture A More Sustainable Garden

Sustainable gardening doesn’t have a firm, technical definition. It’s the concept of using sustainable gardening techniques that not only cause no harm to the...

Cancer Research UK spin-out gets US approval to trial unique T cell therapy

Cancer Research UK’s spin-out, GammaDelta Therapeutics (‘GammaDelta’), has been given approval from the US Food and Drug Administration (FDA) to trial its unique T-cell...

Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy

The ECOG-ACRIN EA1131 study hypothesised that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype triple-negative breast cancer...

Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit [ESMO Virtual Plenary Press Release]

VP6-2021 - IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk,...

Breaking News: Supreme Court Upholds the Affordable Care Act

It’s a great day for cancer survivors. The Supreme Court of the United States (SCOTUS) upheld the Affordable Care Act (ACA), commonly known as...

How Does CAR T-Cell Therapy Work in Treating Cancer?

Craig A. Portell, MD, is an Associate Professor of Medicine at the University of Virginia and a member of the UVA Cancer Center in...